Therapeutic composition containing a mandelamidine derivative

ABSTRACT

IN WHICH R1 AND R2 ARE THE SAME OR DIFFERENT AND EACH REPRESENTS A HYDROGEN ATOM, AN OH GROUP OR A C1-C3 ALKOXY GROUP, OR R1 AND R2 WHEN CONNECTED TOGETHER REPRESENT A 3,4-DIOXYALKYLENE GROUP HAVING FROM 1 TO 3 CARBON ATOMS; R3 REPRESENTS A HYDROGEN ATOM, A STRAIGHT OR BRANCHED C1-C3 ALKYL RADICAL OR A PHENYL GROUP; AND R4 REPRESENTS AN OH GROUP OR C2-C3 ALKYL RADICAL OR PHENYL GROUP, R4 BEING CAPABLE OF REPRESENTING A HYDROGEN ATOM OR A METHYL RADICAL WHEN NEITHER R1 NOR R2 ARE HYDROGEN ATOMS.   1-(R4-N(-R3)-C(=NH)-CH(-OH)-),3-R1,4-R2-BENZENE   THIS INVENTION RELATES TO A THERAPEUTICAL COMPOSITION CONTAINING IN ASSOCIATION WITH AN INERT CARRIER AT LEAST ONE COMPOUND OF THE MANDELAMIDINE SERIES AND THEIR NON TOXIC ACID ADDITION SALTS AS ACTIVE INGREDIENT, SAID COMPOUND CORRESPONDING TO THE FOLLOWING FORMULA:

United States Patent i 3,629,443 THERAPEUTIC COMPOSITION CONTAINING A MANDELAMIDINE DERIVATIVE Louis Lafon, Paris, France, assignor to Societe anonyme (lite: Orsymonde, Paris, France N0 Drawing. Continuation-impart of application Ser. No. 778,315, Nov. 22, 1968. This application Apr. 23, 1970, Ser. No. 31, 366 Claims priority, application Great Britain, Nov. 29, 1967, 54,430/ 67; July 22, 1968, 34,947/ 68; France, Apr. 23,

Int. Cl. A61k 27/00 US. Cl. 424-282 3 Claims ABSTRACT OF THE DISCLOSURE This invention relates to a therapeutical composition containing in association with an inert carrier at least one compound of the mandelamidine series and their non toxic acid addition salts as active ingredient, said compound corresponding to the following formula:

in which R and R are the same or difierent and each represents a hydrogen atom, an OH group or a C -C alkoxy group, or R and R when connected together represent a 3,4-di0xyalkylene group having from 1 to 3 carbon atoms;.R represents a hydrogen atom, a straight or branched C C alkyl radical or a phenyl group; and R represents an OH group or C -C alkyl radical or phenyl group, R being capable of representing a hydrogen atom or a methyl radical when neither R nor R are hydrogen atoms.

This application is a continuation-in-part of application Ser. No. 778,315, filed Nov. 22, 1968, now abandoned.

It envisages the therapeutic compositions containing, in association with a physiologically acceptable and inert carrier, at least one compound of the mandelamidine series as active ingredient, corresponding to the formula:

in which; R, and R taken separately each represent a hydrogen atom, a hydroxy group, a lower alkyl radical such as isopropyl or a lower alkoxy group such as methoxy or R and "R taken together represents a hydrogen atom, a lower alkyl radical such as ethyl, isopropyl, or a phenyl radical and, R represents a hydrogen atom, a straight or branched C -C alkyl radical or a phenyl group, R represents a hydroxy group, a lower alkyl radical having at least two carbon atoms, or a phenyl radical, R also being able to be a hydrogen atom or a methyl radical where R and R do not each represent the hydrogen atom; or one of the non toxic acid addition salts of said compounds and their optical isomers. Lower alkyl is understood here to be radical having at the most 3 3,529,443 Patented Dec. 21, 1971 of a lower aliphatic alcohol, preferably methyl alcohol, on the mandelonitrile of formula:

B1 (II) in which R and R are defined as previously, in order to obtain the corresponding imino-ester. This imino-ester is reacted with an amine of formula:

in which R, and R each represent a hydrogen atom or a lower alkyl radical or phenyl and the corresponding mandelamidine of Formula I is obtained.

In order to obtain the mandelamidines of Formula I in which R represents a OH group (mandelamidoximes) a mandelamidine of Formula I, in 'which R and R are hydrogen atoms obtained according to the above-indicated process, is reacted with hydroxylamine.

For the preparation of the starting 3,4-methylenedioxymandeloni'trile, piperonal is reacted with potassium cyanide in aqueous medium, in the presence of sodium bisulfite as catalyst and of hydrochloric acid diluted to about pH 4.0 to 5.0, operation being carried out in a sealed reaction apparatus.

The following examples illustrate the preparation of certain active principles.

EXAMPLE 1 3,4-dioxy-methylene-mandelonitrile A 20-litre three-necked flask provided with a central helix variable-speed agitation system, an accurate thermometer and a dropper was used. The sealed apparatus communicated with the exterior only by Way of a bubble counter, the outlet from which was connected to a hydrocyanic acid trap. The following substances were introduced into the reactor:

1600 g. of potassium cyanide (23.5 moles) 3000 g. of piperonal (20 moles) 10 litres of water Sealed closure of the apparatus was verified with the aid of the bubble counter. The flask was cooled externally with iced water, agitated to dissolve the cyanide, the piperonal was put into suspension and the temperatures equalised. Then 400 cc. of a solution of sodium bisulphite of density 1.32 was slowly added.

A solution of hydrochloric acid diluted to half (approximately 6 N) was slowly run in, the speed of introduction being regulated so that the temperatures never exceeded 15 C. The introduction of hydrochloric acid was stopped when the pH of the reaction medium reached 4.0 to 5.0.

The nitrile appeared quite rapidly in the form of clear brown oily droplets which settled spontaneously when agitation was stopped. This oily layer was aspirated by a syphon and washed with water three times in a flask having a lower outlet provided with a stirrer.

The nitrile recovered was dissolved in chloroform, then dried over anhydrous calcium chloride for 24 hours. After evaporation of the chloroform in vacuo, approximately 3200 g. of crude product of a brown-orange colour was obtained, having a refractive index at 20 C. of approximately 1.546.

The nitrile so obtained is impossible to distil even under reduced pressure, because it dissociates into an aldehyde and hydrocyanic acid. The purity of the nitrile obtained is suflicient however for it to be used as an intermediate in various syntheses. For example, when treated with anhydrous hydrogen chloride and alcohol in ethereal solution, it reacts to give the corresponding imino-ester with an overall yield based upon the piperonal of approximately 70%.

Operational scheme No. I.Amidines not substituted on the nitrogen atom (R =R =H) EXAMPLE 2 3,4dioxy-methylene mandelamidine hydrochloride A solution of 0.4 mole of 3,4-dioxymethylene-mandelonitrile in 250 ml. of anhydrous ethyl ether and 40 ml. of absolute ethanol was saturated whilst cold with a stream of dry gaseous hydrogen chloride.

After saturation and standing for about 10 hr. at C., the hydrochloride of 3,4-dioxymethylene mandeliminoethyl ester which precipitated was filtered OE and washed twice with 100 ml. of anhydrous ethyl ether.

The product so obtained was dissolved in 300 ml. of cold absolute ethanol. This solution was saturated at 0 C. with a stream of anhydrous gaseous ammonia.

After standing for 2 hours, crude 3,4-dioxymethylenemandelamidine hydrochloride was precipitated by the addition in the cold of 300 ml. of anhydrous ethyl ether. The product was purified by crystallisation from a mixture of ethanol and ethyl ether.

The compound has the form of white crystals. It is soluble in water, methanol and ethanol and insoluble in ethyl acetate, ethyl ether, petroleum ether and benzene. The instantaneous melting point of this compound is 220 C. The yield of 3,4-dioxymethylene-mandelamidine hydrochloride, with respect to the nitrile used in the reaction initially, is 60% altogether.

According to a more advantageous form of the process of the invention, methanol is used in place of ethanol in the first stage and 3,4-dioxy-methylene-mandelimino methyl ester is formed.

(a) Preparation of the imino-ester The following substances were introduced into a 20- litre flask:

6535 g. of the crude nitrile of Example 1 prepared by the reaction of hydrocyanic acid 6000 g. of piperonal (40 moles);

141. of anhydrous chloroform;

1400 g. of anhydrous methanol (44 moles).

The flask was provided with a central helix variablespeed agitation system, an accurate thermometer and a gas inlet tube. The hermetically sealed apparatus communicated with the exterior only via a bubble counter, the outlet of which was connected to a hydrochloric acid trap.

The flask was cooled externally by means of an iced water bath and agitated to equalise the temperatures. Dry gaseous hydrogen chloride was then introduced via the gas inlet tube, the input being regulated so that all was absorbed and the temperature of the reaction medium remained below 25 C.

When the theoretical quantity of hydrogen chloride had been introduced and an output of gas produced at the bubble counter, gas input was stopped and the reaction ceased. The hydrochloride of the imino-ester formed has the appearance of small, dense crystals which can be readily separated. It was recovered by filtration and washed with anhydrous acetone until the filtrate was no longer coloured. It was dried in an oven at about 35 C.

Approximately 7000 g. of a slightly yellow granular product was obtained having no definite melting point.

4 This crude product is utilised for the operations according to (b).

(b) Preparation of the amidine In the 20-litre flask described in (a) externally cooled with iced water, the following substances were introduced:

7000 g. of the imino-ester obtained according to (a); 15 l. of anhydrous ethanol.

The materials were agitated in order to disperse them and to equalise the temperatures. Then dry gaseous ammonia was introduced via the gas inlet tube, the input being regulated so that all was absorbed and so that the temperature of the reaction medium remained at about 20 C. Passage of ammonia was stopped after reaction of an excess of 20-30% with respect to the theoretical amount.

The suspension of the amidine hydrochloride so obtained was left for 24 hours at ambient temperature. It was filtered and the amidine hydrochloride precipitate formed was washed. This was filtered and washed with acetone until the termination of colour in the washings. The product was dried in the oven and had the appearance of a pale grey granular powder weighing approximately 4950 g. This product was purified by recrystallisation from 10 l. of boiling water, slightly acidified with hydrochloric acid in the presence of animal black.

3950 g. of 3,4-dioxymethylene-mandelamidine hydrochloride was obtained, having the appearance of fine, white crystals having a solubility in water at 20 C. of approximately 5%.

The ionised chlorine titre (determined by argentimetry) and the nitrogen titre (measured by protometry in anhydrous media by perchloric acid) are always equal to 1001*: 1%.

The yield after crystallisation was and that of ammonolysis of the imino-ester was 59% The yield with respect to the piperal used for synthesis of the nitrile was higher than 40% Operational scheme No. II.-Amidines substituted on the nitrogen atom.

EXAMPLE 3 N,N- (diethyl-mandelamidine hydrochloride NH OHOHC 0 CgH5 This compound was prepared by the addition of 0.1 mole of mandelimino-ethylester hydrochloride obtained by the action of gaseous HCl on mandelonitrile in the presence of ethanol, according to the method of operation described in Scheme No. I, to a solution of 0.3 mole of diethylamine in ml. of absolute ethanol and heating, under reflux, for 2 hours on a water-bath.

After evaporation under vacuum, the residue was taken up in 100 ml. of water and extracted with ethyl ether to eliminate the excess diethylamine. The aqueous solution was rendered alkaline by the addition of caustic soda. N,N-diethyl-mandelamidine base so displaced was eX- tracted with three 50 ml. quantities of ethyl ether. This ethereal solution was washed with water, dried over anhydrous sodium sulphate, filtered and then evaporated under vacuum.

of which is 167 C., and it is soluble in water, methanol and ethanol and insoluble in ethyl acetate, ethyl ether, petroleum ether and benzene.

Operational scheme No. III.Amidximes.

EXAMPLE 4 Mandelamidoxime Q-CHOHA/ For the preparation of this compound, 0.1 mole of mandelamidine hydrochloride, obtained according to the method of operation described in Scheme No. I was added to a methanol solution of hydroxylamine (0.15 mole of hydroxylamine hydrochloride, 200 ml. of methanol and 0.2 mole of sodium methoxide) The reaction mixture was left for 48 hours at ambient temperature (about 20 C.).

After filtration to eliminate the precipitate of sodium chloride which formed, the methanol solution was evaporated to dryness under vacuum.

50 ml. of Water was added to the residue and the precipitate was washed, the precipitate being constituted by the mandelaminodoxime base which is insoluble in water.

The crude product was purified by crystallisation from a methanol-ethyl ether mixture.

The compound obtained in a yield of 90% has the form of white crystals, the instantaneous melting point of which is 164-165 C. and it is soluble in acidified water, meth anol, ethanol and acetone and insoluble in Water and ethyl ether.

Mandelamidoxime hydrochloride, which precipitates by addition of a solution of HCl in ethyl to an alcoholic solution of the amidoxime, is a hygroscopic product.

The three operational schemes described have been utilised for the preparation of compounds of the invention according to the following Examples 5 to 15. For each compound, the particular operational scheme used is indicated and the salt is indicated in the form in which the compound was obtained, as well as its melting point.

EXAMPLE 5 N-isopropyl-mandelamidine Scheme No. II (HCl; M.P.=209 C.).

EXAMPLE 6 N-phenyl-mandelamidine Scheme No.11 (HCl;M.P.:128-130 C.).

EXAMPLE 7 Meta-hydroxy-mandelamidine Scheme No. I (HCl; M.P.=204 0.).

EXAMPLE 8 N-isopropyl-meta-hydroxy-mandelamidine Scheme No.11 (HCl;M.P.=2l2-2l3 C.).

EXAMPLE 9 Para-hydroxy-mandelamidine Scheme No. I (HCl; M.P.=215 C.).

EXAMPLE 10 3,4-dihydroxy-mandelamidine Scheme No. I (HCl; M.P.=192 C.).

EXAMPLE 11 N-isopropyl-3,4-dihydroxy-mandelamidine Scheme No. II (HCl; M.P.=173 C.).

EXAMPLE 12 3,4-dimethoxy-mandelamidine Scheme No. I (HCl; M.P.=205 C.).

6 EXAMPLE 13 N,N-dirnethyl-3,4-dioxymethylcue-mandelamidine Scheme No. II (HC1;M.P.=212 C.).

EXAMPLE 14 N,N-diethyl-3,4-dioxymethylene-rnandelamidine Scheme No. II (HC1;M.P.=212 C.).

EXAMPLE 15 N-isopropyl-3,4-dioxymethylene-mandelamidine Scheme No.11 (HCl; M.P.=145 C.).

EXAMPLE 16 3,4-methylenedioxy-mandelamidoxime hydrochloride (operational Scheme No. HI-amidoxima) There is slowly added to a solution of 10 g. of 3,4- methylenedioxy mandelamidine hydrochloride (0.043 mole), in 70 m1. of methanol, a solution of hydroxylamine, obtained by adding 3.4 g. of sodium methylate (0.063 mole) to 4.4 g. of hydroxylamine hydrochloride (0.063 mole) in a methanol medium then filtration after 30 minutes of agitation.

After 48 hours rest, evaporation is eifected in vacuo. The residue is added to water gain, filtered, centrifuged and dried in vacuo.

7.3 g. of 3,4-methylene dioxy-mandelamidoxime is obtained (M.P.: 103 C.) which is converted into hydrochloride in solution in ethanol.

The hydrochloride is precipitated by the addition of ethyl ether then purified by crystallisation in an ethanol/ ethyl acetate mixture.

The hydrochloride of the 3,4-methylenedioxy-mandelamidoxime obtained with a yield of (8.5 g.), is in the form of a white powder, soluble in water (at about 20%), methanol, ethanol and insoluble in ethyl ether, petroleum ether, benzene, ethyl acetate. The instantaneous melting point is 165 C.

EXAMPLE 17 1- and d-(3,4-methylenedioxy)-mandelamidine hydrochlorides 29 g. of 3,4-methylenedioxy-mandelamidine hydrochlorides (0.125 mole), in suspension in 30 ml. of Water are treated, cold, by a solution of 6 g. of sodium hydroxide (0.125 mole) in 30 ml. water.

The insoluble basic amidine released is rapidly isolated by filtration, centrifuged and dried in vacuo.

The racemic 3,4-methylenedioxy-mandelamidine, obtained with a yield of 80% (19.5 g.), has been an instantaneous melting point of 118 C.

There is added to a solution of this product (0.1 mole) in 80 ml. ethanol 15.2 g. of l-mandelic acid (0.1 mole), u =l56 (c.=5% in water). Heating is etfected'to 50 C. in order to dissolve everything, crystallisation is allowed to occur and filtering is carried out. 17.3 g. of a product Ia is obtained whose instantaneous melting point is from 1602 C.

The filtrate evaporated to dryness leaves a residue which, added again to ml. of a mixture, of equal volume, of acetone and ethyl ether, supplies after filtration 20 g. of a product 1111 whose instantaneous melting point is from 1324" C.

The product Ia (17.3 g.) recrystallised in ethanol gives 13 g. of a product Ib (M.P.: 1689 C.). The evaporated filtrate leaves a residue which, treated by the acetone/ ethyl ether mixture supplies 3.2 g. of a product IIb (M.P. 132 C.).

, HCl

The product Ila treated by the acetone hot leaves g. of an insoluble substance 10, (MP. 1656 C.). After crystallisation of the acetone solution, 14 g. of a compound He is obtained (M.P. 135-7).

Products Ib (13 g.) and la (5 g.) recrystallised in ethanol enable 16.2 g. of 1- mandelate of 1- (3,4-methylenedioxy)-mandelamidine (compound I) to be obtained whose instantaneous melting point is from 168-9 C. and the rotatory power oc =8 (c.i=0.5% in methanol).

1-( 3,4-methylenedioxy) -mandelamidine The hydrochloride of the l- (3,4-methylenedioxy)- mandelamidine is prepared from the compound I which, in suspension in 30 ml. water, is treated by an excess of hydrochloric acid 5 N.

The 1- mandelic acid released is extracted with three times 100 ml. ethyl ether. The aqueous solution, evaporated in vacuo, leaves a residue which is purified by crystallisation in an ethanol/ethyl ether mixture. 9.2 g. l- (3,4-methylenedioxy)-mandelamidine hydrochloride are obtained with a yield of 63%, which is in the form of a white powder is 160 C. and which has a rotatory power a =70 (c.'=0.5% in methanol).

d-( 3,4-rnethylenedioxy -mandelamidine chlorhydrate The hydrochloride of the d-(3,4-methylenedioxy) mandelamidine is prepared from the compound II (12.5 g.) treated in the same way as described for compound I. 7.2 of d-(3,4 methylenedioxy)-mandelamidine is obtained with a yield of 50%, in the form of prismatic white crystals, the instantaneous melting point of which has rotary power a =+69 (c.=0.5% in methanol).

EXAMPLE l8 1- (3,4-methylenedioxy)-mandelamidoxime A solution of hydroxylamine, prepared from 4.2 g. of hydroxylamine hydrochloride (0.06 mole) and from 3.25 g. of sodium methylate (0.06 mole) in 50 ml. methanol, is added to a solution of 9.2 g. of 1- (3,4-methylenedioxy)- mandelamidine hydrochloride prepared in Example 17 in 50 ml. methanol.

After 48 hours rest, acidification is carried out with an ethanol solution of hydrochloric acid, evaporation is effected in vacuo, the residue is added to water again and the base is precipitated by the addition of sodium acid carbonate. After filtration, 7.4 g. of the basic amidoxime is obtained whose instantaneous melting point is 114 C.

This product, dissolved in ethyl ether is treated by an 1 ethanol solution of hydrochloric acid. The isolated is purified by crystallisation in an ethanol/ethyl acetate mixture.

The 1-(3,4-methylenedioxy)-mandelamidoxine hydrochloride, obtained with a yield of 83% (8.2 g.) is in the form of white crystals, the instantaneous melting point of which is from 1389 C., soluble in water, methanol, ethanol and insoluble in ethyl ether, petroleum ether, benzene, ethyl acetate. It has a rotatory power oc ='-42 (c.=0.5% in methanol).

EXAMPLE 19 d- 3,4-methylenedioxy -mandelamidoxime hydrochloride The following products have also been prepared:

4-isopropyl-mandelamidine, HCl (M.P.: 151 C.)

3-hydroxy-mandelamidine, HCl (M.P.: 204 C.)

4-hydroxy-3-methoxy-mandelamidine, HCl (M.P.: 200

4-methoxy-mandelamidine, HCl (M.P.: 246 C.)

N-phenyl-mandelamidine, HCl (M.P.: 128-130 C.)

N-isopropyl-3-hydroxy-mandelamidine, HCl (M.P. 212- 3-hydroxy-mandelarnidoxime, HCl (M.P.: 184 C.).

The products of the invention supply salts of addition with the acids, and in particular, the chlorhydrates are in form of white crystals soluble in water, methanol ethanol and insoluble in ethyl ether, petroleum ether, benzene, ethyl acetate.

The pharmacological activities of the products according to the invention are illustrated in the following.

EXAMPLE A Toxicological and pharmacological study of the compound of Example 2 is described below using a sample prepared in the laboratory, reference sample No. 1.

Study of the acute toxicity in mice has been carried out.

I.V. administration.Intravenous DL =120:8.7 mg./ kg. (104-138 mg./kg).

Symptoms.exophthalmia, dyspnoea, immediate death by respiratory arrest.

I.M. administration.Intra-muscular DL ranges from 600 to 1000 mg./kg.

Symptoms. Trembling, convulsions, exophthalmia, piloerection pthosis, diminution of respiration.

Gastric administration.No mortality up to 1000 mg./ kg.

Observations on animals which had received 300 mg./ kg. of the product I.M.Piloerection, phtosis, hypothermia (5.5 C.) The product is slightly tranquilising and it protects against mortality due to electric shock.

Study of the cardiovascular properties has been carried out as follows:

(1) Isolated rabbit heart perfused according to the Langendorf method Three isolated rabbit hearts subjected to spasm by barium chloride were perfused with a solution of the product at 10 and mg./l. No clear action was noted on the coronary output nor upon the ventricular amplitude and cardiac rhythm.

(2) Isolated guinea pig auricle The organs were maintained in Lockes liquid at 30 C. aerated by carbogen.

On two organs (right auricle) in doses of 1.2 to 12 micrograms/m1, the product was without action upon the amplitude and rhythm and did not modify the actions of isoprenaline and 1,1 dimethyl-4-phenyl-piperazinium iodine (DMPP) (except in one case where the action of isoprenaline on the amplitude was augmented).

(3) Arterial pressure in anaesthetised rats The animals were anesthetised with urethane. Injection were effected by means of a catheter fixed in the jugular. The AF. was measured at the carotid.

On 2 rats at 12 mg./kg. (1/10 DL I.V. mice), the product caused a hypotensive peak followed by elevation of the pressure by 14% on average for 3 minutes.

(4) Arterial pressure in anaesthetised rabbits The rabbits were anaesthetised with a chloraloseurethane mixture. In one rabbit, the product at 12 mg./kg. I.V. (l/l0 DL I.V. mice): caused a hypotension of 23% for 3 minutes; decreased by 32% the hypertensive action of noradrenaline, did not modify the actions on the pressure of angiotensine, isoprenaline and acetylcholine.

( Arterial pressure in awakened rats.(a) Study by single administration The animals were carrying aortic catheters located at least 24 hours prior to the test.

(A) I.M. administration.Normotensive rats At 50 mg./kg. on 4 rats, the product diminished the pressure up to 19% (on average). This maximum was attained after 30 minutes.

The initial pressure was attained after 30 minutes. The initial pressure was attained again after 1 hour 30 minutes (the hypotensive action is reproducible).

At 300 mg./kg. on 2 rats, it diminished the pressure on average by 59% (maximum) 4 hours after injection. The action showed minutes after injection. The pressure did not increase.

(B) Buccal administration At 50 mg./kg. on a normotensive rat, slight hypotension was immediate and lasted 1 hour 30 minutes. On a hypertensive rat, a slow hypotension was noted which lasted for about 3 hours.

At 100 mg./kg., with normotensive rats, no clear action was noted on 3 rats and an immediate hypotension of average which lasted for 2 hours was noted on 3 rats, which was slower with return action after 6 hours on one other.

With hypertensive rats there was noted:

A hypotension of 54% on average on 2 rats which lasted from 30 minutes to 1 hour after injection and was maintained for more than 6 hours.

At 500 mg./kg. on 2 normotensive rats, a hypotension of 41% on average was noted after between 30 minutes and 1 hour, the maximum being obtained after 3 to 4 hours. One of the treated rats showed an increase after 4 hours and the other showed a low pressure and died the following day.

At 1000 mg./kg. on 1 normotensive rat, a hypotension of 56% was noted, 30 minutes after ingestion of the product, which lasted for more than 6 hours, the animal dying the following day.

(b) Study of a chronic treatment by buccal administration 5 rats received the product in a dose of 100 mg./kg. per day for 4 days. Their pressure was measured by a non sampling method each day, before administration of the product and at hourly intervals after administration, on the first day for 6 hours and on the other days for 3 to 4 hours.

In the course of the first day of treatment, the pressure of the animals decreased by 23%, 30 minutes after administration, and there was a progressive increase (after 6 hours, the drop of pressure was no more than 10%). On the other days, no decrease of pressure was noted.

On the fifth day, the animals received the product I.P. at 50 mg./kg., the pressure dropped by rapidly and returning to its initial level 3 hours after injection.

(6) Arterial pressure in anaesthetised cats The animals were anaesthetised with nembutal. In a dose of 12 mg./kg. I.V. (1/ 10 DL I.V. mice) on 1 cat, the product: caused a hypotension at 8%; slowly increased the hypertensive action of angiotensine; did not modify the hypotensive action of isoprenaline; diminished for more than 1 hour the response of the nictitating membrane to stimulation of the preganglionic fibre of the cervical sympathesis.

It should be noted that, on the hypogastric nervedeferens canal of the guinea pig, the product at 12 micrograms/ ml. did not modify the response to transmural stimulation (4 organs) and that it diminished the response to stimulation of the preganglionic fibre of the nerve (2 organs).

(7) Cardiovascular actions in anaesthetised dogs The dogs were anaesthetised with a mixture of penthiobarbital and chloralose.

At 12 mg./kg. I.V. on one dog (1/ 10 DL I.V. mice), the product: decrease arterial pressure by 17% for more than minutes; did not modify the cardiac frequency, did not modify the systolic pressure in the right ventricle; decreased the amplitude of beating of the right auricle by raising the diastolic pressure and decreasing the systolic pressure; did not modify the pressure actions of adrenaline and isoprenaline; decreased and then briefly increased -(3 minutes) the femoral arterial output.

At 30 mg./kg. I.V. perfused for 10 minutes A DL on 2 dogs, the product: slightly decreased the arterial pressure (9% and -19%); did not modify cardiac frequency; virtually did not modify cardiac output 12% in 1 dog); diminished the cardiac effort by 19% on average, did not modify the peripheral resistance of 1 dog and diminished it by 18% in the other dog.

New tests have also been carried out with a new sample of the product made semi-industrially. This is reference sample No. 2.

The following results have been obtained:

(I) ACUTE TOXICITY IN MICE By gastric administration, no mortality up to a dose of 2 g./kg. was noted.

(I-I) TOLERANCE TO REFERENCE PRODUCT NO. 2 AND ACTION ON A.P. OF AWAKENED DOGS behaviour,

- Hg, the frequency 140 pulses per minute; 50 mn. after injection, the pressure was 115 mm. Hg, the frequency 130 pulses per minute; 3 hours after injection, the pressure was 112 mm. Hg, the frequency 110 pulses per minute; 5 hours after injection, the pressure was 108 mm. Hg, the frquency pulses per minute; the following day, the pressure was 124 mm. Hg, the frequency 110 pulses per minute.

(2) Buccal administration.-At 100 mg./kg. there was observed:

(a) An excellent tolerance and normal behavior;

(b) No action on arterial pressure and cardiac frequency; before administration, the pressure was 107 mm. Hg, the frequency 130 pulses/minute; 30 mn. after administration, the pressure was 100 mm. Hg, the frequency 130 pulses/minute; 50 mn. after administration, the pressure was 930 mm. Hg; 2 hours 30 mn. after administration, the pressure was 100 mm. Hg, the frequency was pulses/ minute; 4 hours after administration, the pressure was 100 mm. Hg, the frequency was 120 pulses/ minute.

In summary, the products of the invention are very well tolerated by dogs by the I.M. and buccal methods of administration. The moderated hypotensive action is manifested particularly by the I.M. route.

In conclusion, the following results have been observed about the behaviour of the product of the invention:

Toxicity in mice.

I.V. DL =120- -8.7 mg./kg.

I.M. D'L between 6-00 and 1000 mg./ kg. Buccal DL50 1 g./'kg.

Action on arterial pressure.

I.V. at 12 mg./kg. (1/10 DL I.V. mice) Anaesthetised rat: hypothen hypertensive Anaesthetised rabbit: hypotensive 1 1 Anaesthetised cat: very slightly hypotensive Anaesthetised dog: hypotensive I.M. at 50 mg./kg. (1/12 DL I.M. mice): hypotensive in awaked rats.

Buccal admn. at 100 mg./kg., hypotensive on first ingestion, none after other administrations in awakened rats.

Cardiovascular action in anaesthetised dogs At 30 mg./kg. at minutes I.V. A DL mice);

Hypotension not due to a reduction in cardiac frequency or to peripheral dilatation;

Diminution of the peripheral vascular resistance and cardiac effort.

Cardiovascular action in awakened dogs Hypotensive action moderated by I.M. administration at 40 mg./kg;

No hypotensive action by buccal administration at 100 mg./kg.;

The tolerance is good by I.M. and buccal administration in awakened dogs.

Also, the action on the heart in anaesthetised dogs has been studied in the following manner:

An electrocardiogram has been recorded, with integration of the cardiac frequency after slow perfusion of the derivative intravenously in a dose of mg./ kg. No modification of the electrocardiographic trace was observed. The cardiac frequency was virtually untouched.

A clinical test described below has been carried out particularly with the product corresponding to Example 2.

(I) Buccal administration Reference product No. 2 of Example No. 1 was administered per os to 10 hypertensive men in a dose of 300 mg. per 24 hours. The total daily dose was divided into 3 eachets corresponding to the following formula:

3,4-dioxymethylene mandelamidine hydrochloride-100 mg. Lactoseq.s.p. one cachet.

In all cases, the test was carried out on patients hospitalised for at least 7 days and Without modification of any parameter likely to modify arterial pressure (regime, activity or other therapy). The base arterial pressure was determined in the 3 days preceding the therapeutic test (between the 7th and 10th days of hospitalisation) and was effectively measured by the Vaquez apparatus, and the palpatory and auscultatory methods. The average base pressure was the average of 9 measurements elfected during the 3 days preceding the therapeutic test.

In the conditions of the therapeutic test, in particular at the doses administered, the product showed itself to be a hypotensive compound of remarkable and constant activity, perfect tolerance and no secondary eifects.

It produced in 10 patients (3 malign hypertensions and 7 moderated hypertensions) an average tensional decrease of =60 mm. Hg for the systolic pressure and of mm. Hg for the diastolic pressure, or a success percentage of 100% and percentage of good results of 100% (allowing as the criterion for a good result the obtaining of a decrease in tension of greater than 40 mm. Hg for the systolic pressure and the obtaining of a degree of improved diastolic pressure of 100 mm. Hg or below).

No non-tolerance nor secondary effect was noted.

(II) Intramuscular administration The product administered I.M. to 3 normotensive men in a dose of mg. by a single injection revealed a powerful and constant hypotensive activity, which was both early (revealed in less than 30 minutes) and prolonged (lasting for over 3 hours), without secondary effects.

The active principle was used in ampoules containing 100 mg. of product in 10 ml. of physiological serum.

As a general conclusion, under the conditions of the therapeutic tests and doses utilised, the medicament of 12 the invention shows a remarkable constant hypotensive activity and excellent tolerance.

The indications for use of the medicament according to the invention are: on the hand, for arterial hypertension whatever its gravity and etiology; on the other hand, for haemorrhagic or ischemic vascular complications of arterial hypertension (cerebral, coronary, visceral or of the limbs) which favours or induces hypertension.

Utilisation of the medicament is also indicated for oral treatment (chronic treatment) or parenteral (emergency treatment).

EXAMPLE B (B) Activities of 3,4-methylenedioxy-mandelamidoxime hydrochloride (Example 6).-(=I) Verification of the acute toxicity and convulsion-producing properties (1) In the mouse-Intravenous administration in the mouse: at 800 mg./kg., the death was observed of 2 animals out of 12 tested.

The symptoms observed are: intense clonic convulsions which last 24 hours in some animals without bringing about death.

Buccal administration in the mouse: no mortality up to the dose of 3 g./kg. From 2 g./kg., the animals show a phase of excitation without convulsion followed by a sedation.

(2) In the rat.-Buccal administration: the dose of 500 mg./kg. causes convulsions in 2 rats out of 5, ptosis on 4 rats out of 5. No mortality.

Buccal administration: the dose of l g./ kg. causes ptosis, convulsions, hypotonia, a paralysis of the hindquarters, hypothermia. The animal is dead 24 hours after having received the dose.

(II) Cardiovascular properties 1) Isolated rabbit heart.-Without barium chloride The product at the dose of 'y/ml. on tWo hearts:

hardly increases the coronary output exerts a positive inotropic eifect does not modify the rhythm With barium chloride.The tests Were carried out on three hearts; the product at the dose of:

100 'y/ml. (1 test):

increases the output by 33% increases the amplitude by 28% reduces the rhythm by 33% 500 'y/ml. (2 tests):

increases the output by +35% and 66% exerts a variable effect on the amplitude --40%+14% does not modify the rhythm.

(2) Arterial pressure of the awakened ratIntramuscular administration0n the three rats, one hypertensive and two normatensive, the product at the dose of mg./kg. reduces the arterial pressure by 40%. The action begins in 10 to 30 minutes. No return to normal is observed even after 6 hours.

Buccal administration: -On three normotensive rats, the product at the dose of 390 mg./kg. per os reduces the arterial pressure by 24% on average after 60 to 90 minutes. The effect starts in 30 to 60 minutes and stops in 90/120 minutes for 2 rats and extends for more than 5 hours for the third.

(3) Arterial pressure of the anaesthetised rabbit.The product at the dose of 77.5 mg./kg. LV. reduces by an average of 49% the arterial pressure of three rabbits after 3 hours. The efiect begins in 15 minutes and extends for more than 5 hours.

(4) Cardiovascular action in the anaesthetised dog.- The product at the dose of 77.5 mg./kg. in intravenous perfusion was administered to a dog.

The results are as follows: fleeting increase by 25% of the difierential arterial pressure by rise in the systolic pressure; very slight increase (9%) of the average arterial pressure which passes from 80 to 87 mm. of mercury; slight reduction (14%) of the arterial pressure in the right ventricle after 15 minutes; reduction in the cardiac frequency -32% after 15 minutes.

The rhythm passes from 155 to 105 pulses/minute: increase in the cardiac output and especially in the systolic output (+78% after 15 minutes); increase in the cardiac index +20% after 15 minutes; increase in the stroke volume index'by 20% at the end of perfusion and by 77% after 15 minutes; increase by 20% in the left ventricular operation for 15 minutes; reduction in the peripheral resistance by 16% after 15 minutes.

A pharmacological study of other compounds of the invention has been made and hereinafter is given the summary of the properties that may be shown in the same manner as those mentioned hereinabove for the product of Example 1.

EXAMPLE C 4-isopropyl-mandelamidine By intravenous administration in the mouse, the DL is 28 rug/kg. Mice having received 15 rug/kg. of the product by intramuscular administration have a very slight hyperthermia and a torsion of the body.

The cardiovascular properties of the product were also studied in the same way as for the product of Example 1:

(1 Isolated rabbits heart.-On 3 hearts perfused by Vandyke Hastings liquid containing barium chloride, the product at the close of 100'y/ml.:

exerts an average coronary dilator effect (+31%) exerts a negative inotropic effect of 35% does not modify the rhythm.

(2) Arterial pressure of the awakened rat.-By intramuscular administration at the dose of 14 mg./kg. an average hypotension of 20% is observed on 3 animals, the maximum effect being between the 2nd and 3rd hour.

EXAMPLE D B-hydroxy-mandelamidine This is a derivative of the guenethidine type, soluble in water, 5 times less toxic than guanethidine and slightly less active. Its DL intravenous administration, in the mouse, is 195 mg./kg. The product was tried orally on a hypertensive man at the dose of 50 mg. per dose, 3 doses per day being absorbed.

The product was used in the form of a cachet or tablet dosed at 50 mg. with an excipient.

A good hypotensive effect was observed after a treatment of 4 weeks in 60% of the cases treated.

EXAMPLE E 3 ,4-dihydroxy-mandelamidine The product in aqueous solution has a pH of 4.

By intravenous administration in the mouse, the DL is 320 mg/kg. The symptoms observed are: sedation, exophthalmus, pile-erection, tachypnea, hematuria and convulsions for doses greater than mg./kg. Death, when it occurred, is due to respiratory stoppage.

By intramcscular administration, no mortality is observed until doses of 600 rng./kg.; the following symptoms are had: sedation, exophthalmus, pile-erection and salivation.

Mice having received by intramuscular administration 160 mgjkg. of the product have-the following symptoms: pile-erection, salivation, exophthalmus, peripheric vasoconstruction and hyperthermia of 1.5 C.

The study of the cardiovascular properties has given the following results:

Isolated rabbits heart (Langendorfi method) vis a vis barium chloride.-On a heart perfused with Vandyke Hastings liquid containing barius chloride, the product at the dose of 'y/ml.

exerts a moderate dilator effect 34% exerts a net positive inotropic effect of does not modify the rhythm.

Without barium chloride:

On two hearts perfused by Vandyke Hastings liquid without barium chloride, the product, at the dose of 100 'y/ml.

exerts a dilator effect 55% exerts a considerable positive inotropic effect +3l0% increases the rhythm by 50% EXAMPLE F 4-hydroxy-methoxy-mandelamidine The product in aqueous solution has a pH of 5.

By intravenous administration in the mouse, the DL is 400 mg./-kg. The animals which die have an accelerated respiration and their death occurs in a few minutes.

Mice having received 200 mg./kg. of the product by intramuscular administration manifested no action on the vegtative nervous system nor any tranquillising or analgesic action.

EXAMPLE G 4-methoxy-mandelamidine (1) Arterial pressure of the awakened rat The product by intramuscular administration at the dose of 60 mg./kg., on 5 anaesthetised rats, causes a maximum hypotension of 20% between the 30th and th minute. The return to normal is not observed in 6 hours.

(2) Arterial pressure of the anaesthetised rabbit The product by intramuscular administration, at the dose of 60 mg./kg., on 10 animals reduces the arterial pressure by 33% after 2 hours. The hypotension begins after 30 minutes. Three hours after the injection, the hypotension is still 29%.

EMMPLE H N -isopropyl-3-hydroxy-mandelamidine By intravenous administration in the mouse, the DL is 36 mg./kg.

By intramuscular administration, it is 135 mg./kg. In strong doses, close to the D L (particularly of the order of mg./kg., convulsions are observed in the animals treated.

The study of the cardiovascular properties has given the following results:

(1) Arterial pressure in the awakened rat By intramuscular administration, the dose of 70 mg./ kg. in 5 rats reduces the arterial pressure on average by 13% except in one case, the hypotensive action begins only late, after 1 to 5 hours. The maximum effect is located between 2 and 3 hours, the return to normal takes place between 5 and 6 /2 hours.

(2) Cardiovascular action in the rat By intravenous administration in a cat at 20 mg./l g. the product reduces the carotid pressure by 40%. It does not modify the pressive action of the adrenaline, acet- 15 ycholine, Tyramine. It increases the hypertension produced by the dimethylphenylpiperazinium. On the nictitating membrane, it exerts no direct effect, does not modify the contractions produced by preand postganglionic stimulations of the upper cervical nerve.

By intra-arterial administration towards the ganglion at doses of 166 and 330 mg./kg., the product slightly (12%) reduces the arterial pressure at the strongest dose. It fleetingly reduces the contractions produced by preand post-ganglionic stimulations of the upper cervical nerve.

The product was used on man at the dose of 25 mg. per dose, 4 tablets or cachets per day with good results in 70% of cases.

EXAMPLE I N-isopropyl-3,4-dihydroxy mandelamidine The product in aqueous solution has a pH of 5.

By intravenous administration in the mouse, the DL is 62.5 mg./kg. The symptoms observed are: dypnea, exophthalmus, peripherio vasoconstriction.

A study of the cardiovascular properties has given the following results:

(1) Isolated rabbits heart On 2 hearts perfused with Vandyke Hastings liquid without barium chloride, the product at the dose of 100/ ml.:

slightly increases the coronary output (+31% exerts a positive inotropic effect (+96% does not modify the rhythm.

(2) Arterial pressure of the anaesthetised rabbit On 5 rabbits, the product at the dose of 31 mg./kg. by intramuscular administration reduces the arterial pressure by 40%.

EXAMPLE I 3-hydroxy-mandelamidoxime By intravenous administration, in the mouse, doses ranging up to 1 g./kg. did not cause any mortality, the animals showing only a phenomenon of pilo-erection. Mice having received 1 g./kg. of the product by intramuscular administration, have presented the following in which R and R are connected together and represent 3,4-dioxyalkylene having from 1 to 3 carbon atoms; R represents hydrogen, or straight or branched C -C alkyl; and R represents H, OH or C C alkyl; in association with a pharmaceutical carrier.

2. A composition as defined in claim 3, containing as active ingredient 3,4-dioXymethylene-mandelamidine or a non-toxic acid addition salt thereof.

3. A composition as defined in claim 1, containing as active ingredient 3,4-dioxymethylene-mandelamidoxime or a non-toxic acid addition salt thereof.

References Cited UNITED STATES PATENTS 9/1960 Hartle et al. 424282 9/1960 Cook et a1 424282 STANLEY J. ER'IE-DMAN, Primary Examiner D. R. ORE, Assistant Examiner U.S. C1. X.R. 424-326 UNITED STATES PATENT GFFICE I Q A L i n L v 1 CGRRLAJ rON December 21, 1971 Patent No. 36294a3 Dated Inventor(s) Louis Lafon It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 16, line 25, change "Claim 3 to --Claim 2--. 7 "7 Signed and sealed this 6th day of June 1972.

(SEAL) Attest:

EDWARD M..FLET C HER JR ROBERT GOTTSCHALK Attssting Officer Commissioner of Patents 

